Sachi Bio
Sachi Bio is a biotechnology company dedicated to advancing RNA-based therapeutics and space-driven drug discovery. They focus on developing innovative treatments for neurodegenerative diseases, cancer, and aging-related disorders by leveraging cutting-edge molecular biology, bioinformatics, and space research. Their mission is to revolutionize therapeutic development through interdisciplinary innovation, including space-based research and microgravity environments to accelerate drug discovery and translation.
Industries
Nr. of Employees
small (1-50)
Sachi Bio
3000 Airport Drive, Unit 201, Erie, CO 80516
Products
Oligonucleotide discovery platform
A discovery engine for designing and optimizing sequence-targeted oligonucleotide molecules for reversible modulation of gene expression and rapid hit-to-lead progression.
Lead brain-penetrant oligonucleotide candidate (neuroinflammation)
A lead oligonucleotide candidate engineered for brain delivery and modulation of neuroinflammatory pathways intended for neurodegenerative disease applications.
Antisense discovery platform for antimicrobial development
Platform methods and workflows to design antisense inhibitors targeting bacterial gene expression to potentiate antibiotic efficacy and address multidrug-resistant infections.
Oligonucleotide discovery platform
A discovery engine for designing and optimizing sequence-targeted oligonucleotide molecules for reversible modulation of gene expression and rapid hit-to-lead progression.
Lead brain-penetrant oligonucleotide candidate (neuroinflammation)
A lead oligonucleotide candidate engineered for brain delivery and modulation of neuroinflammatory pathways intended for neurodegenerative disease applications.
Antisense discovery platform for antimicrobial development
Platform methods and workflows to design antisense inhibitors targeting bacterial gene expression to potentiate antibiotic efficacy and address multidrug-resistant infections.
Services
Partnership programs to co-develop and test sequence-targeted oligonucleotide therapeutics, including organoid studies and space-based experimentation.
Rapid design, synthesis, and in vitro screening of sequence-specific oligonucleotide candidates at scale for target identification and hit optimization.
Execution of in vitro, organoid, and in vivo preclinical studies including PK, biodistribution, and safety assessments to support candidate advancement and regulatory filings.
Identification of key microbial biosynthetic gene clusters and development of sequence-targeted strategies to modulate metabolite production and host-microbiome interactions.
Partnership programs to co-develop and test sequence-targeted oligonucleotide therapeutics, including organoid studies and space-based experimentation.
Rapid design, synthesis, and in vitro screening of sequence-specific oligonucleotide candidates at scale for target identification and hit optimization.
Execution of in vitro, organoid, and in vivo preclinical studies including PK, biodistribution, and safety assessments to support candidate advancement and regulatory filings.
Identification of key microbial biosynthetic gene clusters and development of sequence-targeted strategies to modulate metabolite production and host-microbiome interactions.
Expertise Areas
- Sequence-specific oligonucleotide therapeutics
- CNS-targeted therapeutics and brain delivery
- Preclinical development and IND-enabling studies
- High-throughput drug discovery and automated screening
Key Technologies
- Sequence-specific oligonucleotide design and synthesis
- Brain-penetrant delivery modalities
- High-throughput screening pipelines (>100 targets/run)
- Gram-to-kilogram oligonucleotide manufacturing
News & Updates
Sachi Bio has been selected to provide scientific and commercialization evidence for accelerated aging and drug discovery in space, leveraging their proprietary NanoligomersTM technology to develop a drug-screening pipeline in models of accelerated aging using human brain organoids in space.
Sachi Bio successfully completed and graduated from the Endless Frontier Labs, a start-up accelerator program at NYU Business School, in May 2023.
Sachi Bio has successfully completed and graduated from the CDL 2022-23 cohort, an advanced therapies program, in June 2023.
Sachi Bio was awarded the Healthy Longevity Global Challenge by the National Academy of Medicine for their work in healthy aging.
Recognition for their innovative approach to healthy aging.
Sachi Bio has been selected to provide scientific and commercialization evidence for accelerated aging and drug discovery in space, leveraging their proprietary NanoligomersTM technology to develop a drug-screening pipeline in models of accelerated aging using human brain organoids in space.
Sachi Bio successfully completed and graduated from the Endless Frontier Labs, a start-up accelerator program at NYU Business School, in May 2023.
Sachi Bio has successfully completed and graduated from the CDL 2022-23 cohort, an advanced therapies program, in June 2023.
Sachi Bio was awarded the Healthy Longevity Global Challenge by the National Academy of Medicine for their work in healthy aging.
Recognition for their innovative approach to healthy aging.